Aml Deficiencies

Wise’s US national banking license denial, coupled with a 10% stock drop and media focus on AML/compliance issues, highlights regulatory risk and a potential reapplication pathway under evolving rules (GENIUS Act).

Wise's US national trust bank charter application was rejected by the OCC, triggering a ~7% share drop and ongoing regulatory scrutiny, with a plan to refile under the Genius Act framework; current US operations remain intact.